Immunotherapy in the Peri-Operative Setting of HNSCC

preview_player
Показать описание
Panelists Ezra Cohen, MD; Jared Weiss, MD; and Joshua M. Bauml, MD, discuss the potential for use of pembrolizumab and chemoradiotherapy in the curative setting, as well as safety data for pembrolizumab presented at ASCO 2017.
  1. OncLive
  2. cancer
  3. oncology
Рекомендации по теме
Immunotherapy in the 0:03:45

Immunotherapy in the Peri-Operative Setting of HNSCC

Bladder Cancer: Immunotherapy 0:04:52

Bladder Cancer: Immunotherapy in the Perioperative Setting

MSI-high as a 0:01:03

MSI-high as a biomarker for immunotherapy in perioperative settings

Incorporation of guidelines-concordant 0:05:30

Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC

Clinical case - 0:24:39

Clinical case - Immune Check Point Inhibitor in the perioperative setting for MIBC

Advances in perioperative 0:02:44

Advances in perioperative immunotherapy in lung cancer

Perioperative immunotherapy and 0:02:56

Perioperative immunotherapy and surgery for treating MSI-high esophagogastric tumors

Integrating Perioperative Immunotherapy 0:05:15

Integrating Perioperative Immunotherapy Strategies in NSCLC

UROwebinar: Developments in 1:13:04

UROwebinar: Developments in perioperative immunotherapy for bladder and kidney cancers

Exploring Perioperative Therapies 0:04:04

Exploring Perioperative Therapies and Second-Line Treatments in Bladder Cancer

Realizing the Promise 0:43:46

Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLC

IASLC Webinar: Perioperative 1:01:06

IASLC Webinar: Perioperative Treatment w/Immune Checkpoint Inhibitors in Patients w/Resectable NSCLC

Role for Immunotherapy 0:01:52

Role for Immunotherapy in Perioperative Therapy

Dr Garon on 0:02:13

Dr Garon on Considerations for Perioperative Immunotherapy Use in Lung Cancer

Are We Closer 0:21:36

Are We Closer to a Cure With Perioperative Immunotherapy in Resectable NSCLC?

Unleashing the Potential 0:39:06

Unleashing the Potential of Perioperative Immunotherapy in Resectable NSCLC

Multimodal Management of 0:41:23

Multimodal Management of Early-Stage NSCLC: EGFR-Targeted Therapy in Perioperative Settings

How to Integrate 0:49:11

How to Integrate Perioperative Immunotherapy Into Multimodal Treatment Plans in Resectable NSCLC

Perioperative RCC Treatment: 0:05:09

Perioperative RCC Treatment: Immunotherapy and Urology

Dr. Cascone on 0:01:12

Dr. Cascone on Remaining Challenges With Perioperative Immunotherapy in NSCLC

Perioperative novel systemic 0:07:24

Perioperative novel systemic immunotherapy-based approaches in urinary cancers

Tailoring Your Perioperative 0:05:30

Tailoring Your Perioperative Immunotherapy Approach for Resectable NSCLC

Assessing the role 0:00:54

Assessing the role of perioperative immunotherapy in MIBC

Dr Awad on 0:04:22

Dr Awad on the FDA Approval of Perioperative Nivolumab for Resectable NSCLC